Berlin (Germany) and Germantown, MD (U.S.A.), August 10, 2016 - Epigenomics
AG today announced that it has confidentially submitted a draft
registration statement on Form F-1 to the U.S. Securities and Exchange
Commission (SEC) for a potential U.S. public offering of American
Depositary Shares (ADSs) on the NASDAQ stock market. All ADSs to be sold
in the offering will be offered by Epigenomics AG. It has not been
determined whether or when an offering will be commenced nor have the
number of ADSs or the price range for the offering been determined.
A registration statement relating to these securities has not been filed with the SEC and has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction
A registration statement relating to these securities has not been filed with the SEC and has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction
